New studies add support, and caution, on grapiprant for canine OA

Version 2

Does grapiprant reduce osteoarthritic pain in dogs? The latest answer is yes, probably, but with important caveats. A newly published prospective study in Frontiers in Veterinary Science reported significant improvements in pain and mobility in 36 dogs with naturally occurring osteoarthritis treated with grapiprant, while a 2026 Veterinary Evidence review judged that current evidence supports benefit in chronic, naturally occurring OA, but remains limited and not fully definitive. (frontiersin.org)

That nuance matters because grapiprant has been in practice for years as Galliprant, an EP4 prostaglandin receptor antagonist approved by the FDA in 2016 for the control of pain and inflammation associated with osteoarthritis in dogs. Unlike traditional COX-inhibiting NSAIDs, grapiprant targets the EP4 receptor downstream in the prostaglandin pathway, a mechanism that has helped position it as a differentiated option in canine OA management. The current FDA label continues to list a recommended dose of 2 mg/kg once daily and emphasizes GI, hepatic, renal, and other adverse-event monitoring familiar to clinicians using NSAID-class products. (onlinelibrary.wiley.com)

The strongest earlier clinical evidence remains the randomized, masked, placebo-controlled multisite field trial summarized in the 2026 review and reflected in the label. In that study, 262 dogs were randomized to grapiprant or placebo for 28 days, and treatment successes were significantly higher with grapiprant. Pain interference scores, pain severity scores, and veterinarian total orthopedic scores also improved significantly versus placebo. But the same review points out real limitations: the study population was heterogeneous, lifestyle factors such as diet and exercise were not tightly controlled, dogs were not required to be fasted, and adverse GI signs may have tipped off some pet parents to treatment assignment. (veterinaryevidence.org)

The new Frontiers study pushes the conversation forward by looking beyond clinical scores alone. According to the journal abstract, investigators used a prospective off-on-off design in dogs with naturally occurring OA and found significant gains in mobility and pain measures during grapiprant treatment, alongside plasma metabolomic shifts consistent with reduced inflammation and improved energy metabolism. That doesn’t replace randomized controlled evidence, but it adds biologic plausibility to the clinical signal and may help explain why some dogs appear to improve on therapy. (frontiersin.org)

Still, not every study has been positive. The Veterinary Evidence review also assessed a small induced acute arthritis study and found no significant benefit for grapiprant in that model. The review’s bottom line was measured: one study supported efficacy in client-owned dogs with chronic OA, another did not in acute experimentally induced arthritis, and more research is needed before clinicians can treat the question as settled. (veterinaryevidence.org)

There’s also a broader practice context. A 2024 Frontiers study in young dogs evaluated grapiprant only as part of a standardized multimodal plan that also included fish oil and exercise modification, and the authors explicitly noted that the open-label design and lack of placebo control limit efficacy conclusions. That’s a useful reminder for practitioners: in real-world OA care, grapiprant is often one piece of a larger management plan rather than a stand-alone answer. More recent comparative research has also continued to place grapiprant within a growing field of OA options, including anti-NGF therapy and other multimodal approaches. (frontiersin.org)

Why it matters: For veterinarians, the practical takeaway is that grapiprant has supportive evidence for chronic canine OA pain, but not the kind of broad, unambiguous evidence base that ends debate. It may be especially useful when a clinician wants a labeled OA drug with a targeted EP4 mechanism, or when building a multimodal pain plan for dogs that need an alternative approach. But case selection, monitoring, client communication, and outcome tracking still matter. The evidence supports cautious confidence, not blanket assumptions of superiority or universal response. (animaldrugsatfda.fda.gov)

What to watch: The next important step is better comparative and longer-duration evidence, especially head-to-head trials, placebo-controlled studies in naturally occurring disease, and real-world safety and effectiveness data that show which dogs benefit most, for how long, and in combination with which other OA therapies. (nature.com)